Csl Limited · ASX:CSL

Csl — Investor Presentation (December 2004)

63 slides from Csl's investor presentation, Dec 16, 2004

1. Slide 1: Slide 1

2. Slide 2: Slide 2

3. Slide 3: Contribute as part of a fully integrated, specialist biopharmaceutical company

   4. Contribute as part of a fully integrated, specialist biopharmaceutical company.

4. Slide 4: Manufacturing - synergies achieved

   manufacturing - synergies achieved ti‘ ‘(C(‘(‘(‘(‘(;(SNRNN(C

5. Slide 5: CSL Bioplasma

   Sy <j y CSL Bioplasma hg © Specialty products . Vaccinology @ AIPL e Laboratories 4 Parkville, Australia __ © Marburg, Germany ¢ Broadmeadows, Australia ¢@ Marburg, Germany e Bern, Switzerland © Bern, Switzerland o

6. Slide 6: Staff and investment

   ol ~5O0 staff ~A$140M ti‘ ‘(C(‘(‘(‘(‘(;(SNRNN(C

7. Slide 7: Project review

   Project Review Identif Evaluation Operations Performance Analytical Financial Deal Making Testing Ss trategy Poy

8. Slide 8: Slide 8

9. Slide 9: Slide 9

10. Slide 10: Slide 10

11. Slide 11: Dengue: NIH preclinical/clinical grants

    ee .- Dengue: NIH prec inical/cl inica grants oO (Hawaii Biotech) * Proceedings of the National Academy of Science (USA) 101:10697, ms

12. Slide 12: Plasma Product Director, ZLB Behring

    ~ 8 "Blob Director of Plasma Product ONE _ ZLB Behring

13. Slide 13: Registrations to expand marketing reach

    Hs i ay PRs a Ey, y PEO Co o registrations to expand marketing reach. —

14. Slide 14: Slide 14

15. Slide 15: Slide 15

16. Slide 16: Broad portfolio of products - Global Sales Reach

    TERE Broad portfolio of products - Global Sales Reach

17. Slide 17: Slide 17

18. Slide 18: Main products: hemophilia, critical care, wound healing

    Uy i Bhi GOT E LEGA to} is as EMULE, Beare fetes paces ws ea Mee F II+III Main Hi hill Critical C fe jaemophilia ritical Care products tVvie* — (es) Wound Healing @ > Centre of Excellence

19. Slide 19: Slide 19

20. Slide 20: Other projects

    Other projects rHDL process Pathogen Safety

21. Slide 21: Chromatographic process

    SS MANS Be he os eye IS NINE ae De Sires oN wer ts Cans MI sh hy ee ; Mae Oeaed Cen ns (12%, IV) Chromatographic (10% IV) ti(‘i‘_i‘i‘i‘(‘(‘(‘(‘(‘(C(CSRNRN(N(C(CAR

22. Slide 22: Improving diagnosis of immunodeficiency

    a RAE eet ey BU DOVE ide Te Lo . Improving diagnosis of immunodeficiency : a The Jeffrey Modell Diagnostic Center for Primary _ Immunodeficiencies at The Children's Hospital of Philadelphia

23. Slide 23: Purity

    h d and purit

24. Slide 24: Nov 04, TTP

    Nov 04, TTP

25. Slide 25: IVIG in Neurological Diseases

    \@ INDAPS 2G ky HELMEM OGIeA, SN EASE 1? AA RACHIG HYREOSIOM: 1-75 Noveunber 200 ___ IVIG in Neurological Diseases : e Exploring new indications

26. Slide 26: Anti D for ITP submissions

    e Anti D for ITP submissions G1 O05 ti‘ ‘(C(‘(‘(‘(‘(;(SNRNN(C

27. Slide 27: YEE TEER SGI

    YEE TEER SGI vy IEE ET EE fs) Ue Vege ee i aa DA my wy VE ey Wes, Aas LAS y ee REL a _ ie | CA } 457 Cm fF pe ie ee ye Le Lo LD a ys Le Le ee yy 2 Le Le Leds fom LD Ve Ly _ oo ey eye Te Le i By oe So Lines 7 Lapp eled Ye ey VOLE: Ve ae _ al Lo Sy y 2 el y of wn hd patie oo 2 Le 2 ny i Hel d Ss 9 5 "

28. Slide 28: Market leader in vWF concentrate

    Market leader in vWF concentrate ti‘ ‘(C(‘(‘(‘(‘(;(SNRNN(C

29. Slide 29: Slide 29

30. Slide 30: Fibrinogen and thrombin

    fibrinogen and thrombin - Distributed by ZLB Behring in Japan ti‘ ‘(C(‘(‘(‘(‘(;(SNRNN(C

31. Slide 31: HAE patients vs healthy subjects

    LLL LLL, HAE patients Healthy subjects Nielsen, J of Int Med 1996; 239: 119 oe

32. Slide 32: va oS

    va oS am AA x: a Bae Sn 4 > Ce EF oe Co BE Ir en

33. Slide 33: ompel

    ompel action.

34. Slide 34: Slide 34

35. Slide 35: Slide 35

36. Slide 36: Low pH treatment

    = LowpHtreatment ~*~” e Emerging viruses (e.g West Nile, SARS) inactivated by these processes.

37. Slide 37: Complementary laboratories maintaining state of the art virology

    Complementary laboratories maintaining state of the art virology and prion technologies. ti‘ ‘(C(‘(‘(‘(‘(;(SNRNN(C

38. Slide 38: New initiatives underway

    e New initiatives underway

39. Slide 39: Slide 39

40. Slide 40: Slide 40

41. Slide 41: Ne We

    ul Ne We

42. Slide 42: Slide 42

43. Slide 43: Slide 43

44. Slide 44: Slide 44

45. Slide 45: Magnetic Resonance scan

    Magnetic Resonance scan) ti‘ ‘(C(‘(‘(‘(‘(;(SNRNN(C

46. Slide 46: Slide 46

47. Slide 47: Slide 47

48. Slide 48: Chest pain with or without permanent damage

    - results in chest pain with or without permanent - damage

49. Slide 49: Plaque rupture and myocardial infarction

    Morera ortery Farky athsroms: “unerable” plac * Thin titres cap © Lage Hpved co! «Many inflarrirnatcry: eres * Thick Mbrous cag * Presorved iumnen Thirardborsics ed a rapturedt mlague Smooth: "ree eats. ™ Achwentibies Heated rupturect plage = Slarreney Tarver « Fibrous ition Fight coronary artery Li

50. Slide 50: Pluto and Beyond

    "PLUTO AND BEYOND © Extreme Lasers: Rent a Rain Forest When Whales Walked

51. Slide 51: Slide 51

52. Slide 52: Slide 52

53. Slide 53: cd jess phones of Artie clinical ppobiens

    2 cd jess phones of Artie clinical ppobiens

54. Slide 54: Slide 54

55. Slide 55: Canada - high quality clinical trial infrastructure

    Canada - high quality clinical trial infrastructure ti‘ ‘(C(‘(‘(‘(‘(;(SNRNN(C

56. Slide 56: Guidewire

    Guidewire shadow Schoenhagen ef al, Clev Clin J Med 2003

57. Slide 57: Nissen, Am J Cardiol 2002 PH

    Nissen, Am J Cardiol 2002 PH

58. Slide 58: Slide 58

59. Slide 59: Slide 59

60. Slide 60: Slide 60

61. Slide 61: Slide 61

62. Slide 62: AIRY IOS

    AIRY IOS

63. Slide 63: With Aventis

    with Aventis e Topical delivery for eye disease patent issued ti‘ ‘(C(‘(‘(‘(‘(;(SNRNN(C

CSL — Investor Presentation (December 2004) on 6ix